145 related articles for article (PubMed ID: 31675404)
1. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature.
Ensslin CJ; Kao PH; Wu MY; Chang YY; Kuo TT; Hsieh CH; Hsieh SY; Yang CH; Miller LS
Cutis; 2019 Sep; 104(3):E11-E15. PubMed ID: 31675404
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
3. Image Gallery: Sorafenib-induced acne of the buttocks.
Kiritsi D; Arnold AW
Br J Dermatol; 2017 Dec; 177(6):e351. PubMed ID: 29313937
[No Abstract] [Full Text] [Related]
4. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
5. [Nodulocystic eruption induced by sorafenib].
Chambelland A; Koeppel MC; Desmedt E; Fongue J; Buono JP; Berbis P; Delaporte E
Ann Dermatol Venereol; 2019 Oct; 146(10):646-654. PubMed ID: 31362839
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
8. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M
Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819
[TBL] [Abstract][Full Text] [Related]
10. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
[TBL] [Abstract][Full Text] [Related]
11. Facial nodulocystic eruption induced by sorafenib in a patient with hepatocellular carcinoma.
Duran-Vian C; Gómez-Fernández C; Navarro-Fernández I; Del Cura LR; Alonso-Buznego L; González-Vela MC; González-López MA
Indian J Dermatol Venereol Leprol; 2020; 86(4):409-411. PubMed ID: 32415051
[No Abstract] [Full Text] [Related]
12. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Liang CP; Yang CS; Shen JL; Chen YJ
Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
[No Abstract] [Full Text] [Related]
13. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
Lederhandler M; Beasley JM; Brinster NK; Nagler AR
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677801
[TBL] [Abstract][Full Text] [Related]
14. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
15. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
16. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
[TBL] [Abstract][Full Text] [Related]
17. Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.
Nunes G; Fonseca C; Patita M; Aleixo MJ; Ramalho M; Fonseca J
Turk J Gastroenterol; 2020 Feb; 31(2):184-186. PubMed ID: 32141829
[No Abstract] [Full Text] [Related]
18. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective.
Pearson H; Marshall LV; Carceller F
Pediatr Hematol Oncol; 2020 Aug; 37(5):412-423. PubMed ID: 32183592
[TBL] [Abstract][Full Text] [Related]
20. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Borgia F; Saitta C; Vaccaro M; Franzè MS; Lentini M; Cannavò SP
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):327-331. PubMed ID: 28825507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
